Journal of
Infectious Diseases and Immunity

  • Abbreviation: J. Infect. Dis. Immun.
  • Language: English
  • ISSN: 2141-2375
  • DOI: 10.5897/JIDI
  • Start Year: 2009
  • Published Articles: 83


Cost effectiveness analyses of influenza A (H1N1) vaccination programs: How accurate were they?

Michael F. Beeler*
  • Michael F. Beeler*
  • Department of Mechanical and Industrial Engineering, University of Toronto, Canada. Operations Research Center, MIT, Cambridge, MA, USA.
  • Google Scholar
Dionne M. Aleman
  • Dionne M. Aleman
  • Department of Mechanical and Industrial Engineering, University of Toronto, Canada.
  • Google Scholar
Michael W. Carter
  • Michael W. Carter
  • Department of Mechanical and Industrial Engineering, University of Toronto, Canada.
  • Google Scholar

  •  Received: 16 September 2013
  •  Accepted: 05 November 2014
  •  Published: 30 November 2014


Aleman DM, Wibisono TG, Schwartz B (2011). A non-homogeneous mixing model for predicting pandemic spread. Interfaces Special Issue on Humanitarian Applications: Doing Good with OR. J. Interfaces 41:301-315.
Amico C (2009). How Much Will the H1N1 flu cost the U.S.? Retrieved February 5, 2012. Available at:
Arnesen T, Trommald M (2004). Roughly right or precisely wrong? Systemic review of quality-of-life weights elicited with the time trade-off method. J. Health Ser. Res. Policy 9:43-50.
Blackwell T (2010). Ottawa H1N1 spending too high, ineffective: critics. Retrieved February 5, 2012. Available at:
Canadian Agency for Drugs and Technology in Health (2006). Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Available at:
CBC News (2009). Canada to order 50.4 million H1N1 vaccine doses; $400M contract goes to GlaxoSmithKline factory in Quebec City. Retrieved February 3. Available at:
Centers for Disease Control and Prevention (2010b). 2009 H1N1 Vaccine Doses Allocated, Ordered, and Shipped by Project Area. Retrieved February 2012. Available at:
Centers for Disease Control and Prevention (2010a). CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 - February 13, 2010. Retrieved February 4, 2012. Available at:\_H1N1\_Estimates\_031210\_final.pdf
Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer A (2011). Discounting and decision making in the economic evaluation of health care technologies. Health Econ. 20:2-15.
Durbin A, Corallo A, Wibisono T, Aleman DM, Schwartz B, Coyte PC (2011). A cost effectiveness analysis of the H1N1 vaccine strategy for Ontario, Canada. J. Infect. Dis. Immunol. 3:40-49.
Gojovic M, Sander B, Fisman D, Krahn M, Bauch C (2009). Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 181:673-680.
International Society for Pharmacoeconomics and Outcomes Research. (2014). Pharmacoeconomic Guidelines Around the World: Comparative Table. (ISPOR) Retrieved October 27, 2014. Available at:
Khazeni N, Hutton D, Garber AM, Hupert N, Owens DK (2009). Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann. Intern. Med. 151:829-840.
Lee BY, Brown ST, Korch GW, Cooley PC, Zimmerman RK, Wheaton WD, Zimmer SM, Grefenstette JJ, Bailey RR, Assi TM, Burke DS (2010). A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine 28:4875-4879.
Loper R, Lang D, Hill S (2003). Use of pharmacoeconomics in prescribing research. Part 3: cost-effectiveness analysis: a technique for decision-making at the margin. J. Clin. Pharm. Ther. 28:243-249.
Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, Dunham KM, Meltzer MI (2011). Cost-Effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States. PLoS ONE 6:e22308.
Public Health Agency of Canada. (2010). Fluwatch April 11 to April 17, 2010 (Week 15). Retrieved February 18, 2012. Available at:\_10/index-eng.php
Reuters (2010). U.S. scales back H1N1 vaccine, cuts CSL order in half. Retrieved February 18, 2012. Available at:
Robberstad B (2005). QALYs vs DALYs vs LYs gained: What are the differences, and what difference do they make for health care priority setting? Norsk Epidemiol. 14:183-191.
Salomon S, Murray C (2004). A multi-method approach to measuring health-state valuations. Health Econ. 13:281-290.
Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, Maetzel A, McGeer A, Raboud J, Scales DC, Gojovic MZ, Krahn M (2010). Is a mass immunization program for pandemic (H1N1) good value for money? Evidence from the Canadian experience. Vaccine (28):6210-6220.
Sander B, Bauch C, Fisman DN, Fowler R, Kwong JC, McGeer A, Zivkovic Gojovic M, Krahn M (2009). Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Early evidence from the Canadian experience. PLoS Curr. 17:1:RRN1137.
Severens J, Milne R (2004). Discounting Health Outcomes in Economic Evaluation: The Ongoing Debate. Value Health 7:397-401.
Smith D, Gravelle H (2001). The practice of discounting in economic evaluations of healthcare interventions. Int. J. Technol. Assess. Health Care 17:236-243.
Torgerson D, Raftery J (1999). Discounting. BMJ Economics notes 319:914-915.
Waldie P, Alphonso C (2009). Cost of vaccinating nation hits $1.5 billion and climbing. Retrieved February 5, 2012. Available at:
Wilson N, Baker MG (2009). The Emerging Influenza Pandemic: Estimating the Case Fatality Ratio. Eur. Surveill. 14(26). pii: 19255.
Yarmand H, Ivy J, Roberts S, Bengtson M, Bengtson N (2010). Cost-effectiveness analysis of vaccination and self-isolation in case of H1N1. In: Johansson B, Jain S, Montoya-Torres J, Hugan J, Yucesan E (Ed.), Proceedings of the 2010 Winter Simulation Conference. pp. 2199-2210.